Illumina Stock Plunges 14%, Wiping Out $6.1 Billion Despite Raised 2026 Profit Outlook

The DNA-sequencing company lifted its full-year earnings and sales forecasts, but third-quarter revenue missed analyst estimates by $20 million.

Share
Illumina Stock Plunges 14%, Wiping Out $6.1 Billion Despite Raised 2026 Profit Outlook

Illumina, which makes DNA-sequencing tools, plunged 13.86% to $249.86 in Friday trading, as of 9:48 a.m. ET, erasing $6.1 billion in market value a day after it raised its 2026 profit forecast. Third-quarter revenue came in below analyst estimates, and the stock had roughly doubled this year.

Beat on profit, miss on sales

Third-quarter revenue was $1.13 billion, $20 million short of analyst estimates. Adjusted earnings of $1.44 a share beat those estimates by $0.08.

The company's 8-K filed Thursday lifted the lower end of its profit range: $5.30 becomes $5.40, with the top at $5.45, before tariff refunds. Its new 2026 revenue outlook, also excluding tariff refunds, is $4.64 billion to $4.66 billion.

A stock priced for more

Illumina shares were up about 121% this year at Thursday's close, against about 13% for the S&P 500. The stock sat within 2% of its highest close of the past year, set on October 5, before Friday's session, so expectations for the report were high.

The drop was on pace to be its biggest one-day fall in at least 275 trading sessions, since Sept. 26, 2025. Investor's Business Daily attributed the slide to tariff confusion and a shaky backdrop for AI-linked tech stocks.

A slide goes away

On the earnings call, the chief financial officer said Illumina will stop showing its slide tracking customers' shift to the NovaSeq X sequencer after the fourth quarter, because that conversion is nearing completion.

The market value lost, about $6.1 billion, left Illumina near $37.7 billion at Friday's morning price.

Sources

More on Illumina

All Illumina (ILMN) coverage →